{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:26:56Z","timestamp":1776522416997,"version":"3.51.2"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diuretic agents are prohibited in sports in\u2010 and out\u2010of\u2010competition according to the regulations of the World Anti\u2010Doping Agency (WADA) because of their possible masking effects on other doping agents in urine samples, and their ability to produce fast acute weight losses. Despite previous studies reported adverse analytical findings (AAFs) resulting from contaminations at ppm level (\u03bcg\/g) of medicinal products, and recommended to introduce reporting limits for diuretics in doping controls, these are not adopted in analyses performed by WADA\u2010accredited laboratories. We report the case of an athlete with two AAFs for hydrochlorothiazide (HCTZ) at low urinary concentrations (&lt;10\u00a0ng\/mL), who declared the use of nutritional supplements prepared in a compounding pharmacy. His nutritional supplements were analyzed revealing HCTZ presence in different concentrations, at the ppm level (\u03bcg\/g and ng\/mL).<\/jats:p><jats:p>With the aim of testing the plausibility of the observed urinary HCTZ concentrations with the nutritional supplement ingestion, a urinary excretion study with three healthy volunteers was performed. HCTZ\u2010contaminated powder (6.4\u00a0\u03bcg\/g of HCTZ) was administered to each subject in different dosages, reproducing the possible ingestion pattern occurred. Urine specimens were collected before and after ingestion of the powder, up to 24\u00a0hours, and underwent liquid\u2013liquid extraction and liquid chromatography\u2013tandem mass spectrometry determination.<\/jats:p><jats:p>Post\u2010administration specimens were found to contain HCTZ at concentrations of 5\u2013230\u00a0ng\/mL, which supported the accidental inadvertent intake of the prohibited substance by the athlete. This study makes the argument that the introduction of reporting limits for diuretics are warranted in doping control samples, in order to protect against inadvertent AAFs due to contaminated products.<\/jats:p>","DOI":"10.1002\/dta.2499","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T16:59:13Z","timestamp":1536425953000},"page":"512-522","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Multiple incidence of the prescription diuretic hydrochlorothiazide in compounded nutritional supplements"],"prefix":"10.1002","volume":"11","author":[{"given":"Donata","family":"Favretto","sequence":"first","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-0120","authenticated-orcid":false,"given":"Sindi","family":"Visentin","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Scrivano","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Roselli","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Mattiazzi","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pertile","sequence":"additional","affiliation":[{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Vogliardi","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Tucci","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Montisci","sequence":"additional","affiliation":[{"name":"Department of Cardiac Thoracic and Vascular Sciences and Public Health University of Padova  Padova Italy"},{"name":"University Hospital of Padova  via Falloppio 50 35121 Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.05021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00789.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(85)80017-0"},{"key":"e_1_2_9_5_1","first-page":"134","article-title":"The influence of diuretics on the excretion and metabolism of doping agents. II Phentermine","volume":"36","author":"Delbeke FT","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_9_6_1","first-page":"1413","article-title":"The influence of diuretics on the excretion and metabolism of doping agents. III Etilamfetamine","volume":"36","author":"Delbeke FT","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/bod.2510090203"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(91)80232-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510120105"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2016.08.029"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.9.665"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3945\/jn.115.211102"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101093"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1079\/NRR2006122"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0363546509344071"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/02640410400023258"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941738117727736"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/19440049.2013.800649"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2016.06.018"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341970"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1452"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1123\/ijsnem.2017-0429"},{"key":"e_1_2_9_23_1","unstructured":"Council of Europe.Committee of Ministers. Resolution CM\/Res(2016)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients.2016. Available athttps:\/\/www.edqm.eu\/sites\/default\/files\/resolution_cm_res_2016_1_quality_and_safety_assurance_requirements_for_medicinal_products_prepared_in_pharmacies.pdf(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_24_1","unstructured":"Commission of the European Community.Commission Directive 2003\/94\/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use.2003. Available athttps:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol\u20101\/dir_2003_94\/dir_2003_94_en.pdf(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_25_1","unstructured":"Pharmaceutical Inspection Convention Pharmaceutical Inspection Co\u2010Operation Scheme.PIC\/S Guide to Good Practices for the Preparation of Medicinal Products in Healthcare Establishments.2014. Available athttps:\/\/www.picscheme.org(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2014.07.010"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4907-615"},{"key":"e_1_2_9_28_1","unstructured":"U.S. Anti\u2010Doping Agency.Pharmacy Compounding. Available athttps:\/\/www.usada.org\/substances\/pharmacy\u2010compounding\/(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1123\/ijsnem.2017-0050"},{"key":"e_1_2_9_30_1","unstructured":"U.S. Food and Drug Administration.Federal Food Drug and Cosmetic Act (FD&C Act). Available athttps:\/\/www.fda.gov\/regulatoryinformation\/lawsenforcedbyfda\/federalfooddrugandcosmeticactfdcact\/default.htm(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_31_1","unstructured":"European Parliament and Council of European Union.Directive 2002\/46\/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements.2002. Available athttps:\/\/eur\u2010lex.europa.eu\/legal\u2010content\/EN\/TXT\/PDF\/?uri=CELEX:32002L0046&from=EN(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_32_1","unstructured":"World Anti\u2010Doping Agency.Anti\u2010doping Testing Figures2016. Available athttps:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/2016_anti\u2010doping_testing_figures.pdf(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2336"},{"key":"e_1_2_9_34_1","unstructured":"U.S. Anti\u2010Doping Agency.U.S. Volleyball Athlete Alexandra Klineman Accepts Finding of No Fault for Anti\u2010Doping Rule Violation.2017. Available athttps:\/\/www.usada.org\/alexandra\u2010klineman\u2010accepts\u2010finding\u2010no\u2010fault\/(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_35_1","unstructured":"U.S. Anti\u2010Doping Agency.U.S. Paralympic Alpine Skier Staci Mannella Accepts Finding of No Fault.2018. Available athttps:\/\/www.usada.org\/staci\u2010mannella\u2010accepts\u2010finding\u2010no\u2010fault\/(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_36_1","unstructured":"U.S. Anti\u2010Doping Agency.U.S. Gymnastics Athlete Shaldybin Accepts Finding of No Fault for Anti\u2010Doping Rule Violation.2016. Available athttps:\/\/www.usada.org\/kristen\u2010shaldybin\u2010accepts\u2010finding\u2010of\u2010no\u2010fault\u2010for\u2010anti\u2010doping\u2010rule\u2010violation\/(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_37_1","unstructured":"Cyclingnews.com.Impey cleared after Probenecid positive.2014. Available athttp:\/\/www.cyclingnews.com\/news\/impey\u2010cleared\u2010after\u2010probenecid\u2010positive\/(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2009.01.032"},{"key":"e_1_2_9_39_1","unstructured":"World Anti\u2010Doping Agency.International standard for laboratories (ISL).2016. Available athttps:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/isl_june_2016.pdf(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_40_1","unstructured":"World Anti\u2010Doping Agency.Technical Document \u2013 TD2018MRPL. Technical Document for minimum required performance levels.2018. Available athttps:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/td2018mrpl_v1_finaleng.pdF(Accessed 22\/07\/2018)."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.08.017"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1705"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1471"},{"key":"e_1_2_9_44_1","unstructured":"World Anti\u2010Doping Agency.Technical Document \u2013 TD2013MRPLv1.0. Explanatory Note \u2013 Summary of major Modifications. Available athttps:\/\/www.wada\u2010ama.org\/sites\/default\/files\/resources\/files\/WADA\u2010TD2013MRPL\u2010Summary\u2010modifications\u2010EN.pdf. (Accessed 22\/07\/2018)."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.2499","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:19:07Z","timestamp":1760386747000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/dta.2499"],"URL":"https:\/\/doi.org\/10.1002\/dta.2499","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"2018-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}